RenaSci is a leading provider of consultancy and non-clinical experimental services to evaluate the risks posed by novel CNS drugs for abuse and physical dependence. We offer the complete package of GLP-compliant non-clinical models to support the regulatory evaluation of centrally acting drugs (self-administration, drug discrimination and withdrawal-induced physical dependence) together with the expertise to prepare the associated regulatory documentation to support Market Approval Authorisation and New Drug Applications. Our non-clinical studies and reports together with our regulatory expertise have provided our clients with many successful US and European drug approvals.
Get in touch to find out how these neurochemical and behavioural assays can provide an early assessment of abuse potential of novel drugs.
For more details or information on how we can support your project please complete the contact form.